🇺🇸 FDA
Pipeline program

deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

IM011-1071

Phase 3 small_molecule active

Quick answer

deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib for Juvenile Psoriatic Arthritis (JPsA) is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bristol-Myers Squibb / Pfizer EEIG
Indication
Juvenile Psoriatic Arthritis (JPsA)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials